Sunday, 3 September 2017

8YRS OLD IIH X Younger age at presentation with PTCS was found to be a risk factor for treatment failure or relapse.

J Neuroophthalmol  |  Posted 2 weeks ago

Treatment Response in Pediatric Patients With Pseudotumor Cerebri SyndromeTovia E, Reif S, Oren A, Mitelpunkt A, Fattal-Valevski A; Journal of Neuro-Ophthalmology (Aug 2017)

BACKGROUND Pseudotumor cerebri syndrome (PTCS) is a disorder defined by increased intracranial pressure in the absence of an intracranial space-occupying lesion. This retrospective study aimed to examine the outcomes in children with PTCS.
METHODS Data was collected retrospectively from the charts of consecutive pediatric patients treated for PTCS at our hospital between 2000 and 2007 (60 patients; 36 females, 24 males).
RESULTS Forty-six patients (76.6%) responded well to acetazolamide therapy, with full resolution of symptoms, including papilledema (average treatment duration 1 year; range: 1 month-5 years). Of the 14 patients with no response to treatment, 9 (23.4%) required surgical intervention. Nonresponders tended to be younger at presentation (8.7 vs 11.5 years, P = 0.04). Twelve patients (26%) experienced relapse after acetazolamide was discontinued. The group that experienced relapse was significantly younger than the nonrelapsers (8.9 vs 12.1 years, P<0 .05="" p="">
CONCLUSIONS Younger age at presentation with PTCS was found to be a risk factor for treatment failure or relapse.

No comments: